In the medicine market, most newly introduced drugs and drug candidates show poor water solubility, which prevents their absorption in the body. This, in turn, limits their therapeutic efficiency.
Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a series of professional education sessions, focused on how end users of Mitosol® can achieve compliance with USP <800>, the soon to be implemented and enforced standards for control of hazardous drugs in healthcare facilities.
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.
May is Mental Health Awareness Month. Get your mental health news here.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research published in The New England Journal of Medicine and led by an oncologist from Dana-Farber Cancer Institute.
Most antidepressants used for chronic pain are being prescribed with “insufficient” evidence of their effectiveness, scientists have warned.
A new advanced artificial intelligence (AI) system has shown world-leading accuracy and speed in identifying protein patterns within individual cells.
A new drug delivery system delivers an antioxidant directly to mitochondria in the liver, mitigating the effects of oxidative stress.
The U.S. Food and Drug Administration has approved Arexvy, the first RSV vaccine cleared for use in the United States. Arexvy has been in development for years, and is based on structural biology work done at the Advanced Photon Source between 2009 and 2013.
In this study, patients using medical cannabis reported improvements in health-related quality of life, which were mostly sustained over time. Adverse events were rarely serious but common, highlighting the need for caution with prescribing medical cannabis.
We’ve all recently gotten a crash-course in drug repurposing, thanks to near-daily news reports about efforts to identify existing medicines that could help treat COVID-19 in the early phase of the pandemic.
Many people have experienced infections from E. coli, which are primarily seen as inconvenient and unpleasant. For some patients, like those with blood cancer, however, there is a risk that the bacteria will travel into the bloodstream.
According to a new Johns Hopkins Medicine study, low pain self-efficacy can predict daily pre-surgery prescribed opioid use among patients seeking elective spine surgery.
Nucleus RadioPharma, a radiopharmaceutical company founded by Eclipse and Mayo Clinic, announced today it has received approval from the Minnesota Department of Employment and Economic Development (DEED) for its economic incentive request to support a facility in Rochester.
In a first-of-its-kind analysis, Cornell University researchers and partners found that pharmaceutical producers could reduce their environmental impact by roughly half by optimizing manufacturing processes and supply chain networks and by switching to renewable energy sources.
In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone.
A sharp increase in the price of the gout drug colchicine, the result of an unusual FDA policy, led to lower use and poorer disease control. The findings have implications for other drugs, whose price could be similarly affected by government policies and manufacturer decisions.
Although the On-X aortic valve and apixaban have been approved for use by the U.S. Food and Drug Administration (FDA), they had not been approved to be used together. Between May 2020 and September 2022, the PROACT Xa randomized, multicenter, open-label trial compared the direct factor Xa inhibitor apixaban (Eliquis) with warfarin in patients with bileaflet carbon aortic valves.
The researcher discusses the findings in a new study on the efficacy and safety of fecal microbiota (REBYOTA™), the first microbiota-based live biotherapeutic approved by the US FDA used to prevent recurrent Clostridioides difficile infection in adults.
Worms might not be depressed, per se. But that doesn’t mean they can’t benefit from antidepressants.
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues.
Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive. Now scientists at Washington University School of Medicine have identified a potential pathway to pain relief that neither triggers addiction nor causes hallucinations.
With an emphasis on reaching the entire spectrum of allied health professionals working within primary care, Philadelphia College of Osteopathic Medicine (PCOM) is launching its first peer-reviewed scientific journal, the Journal of Integrated Primary Care (JIPC).
A new study found a declining proportion of DATA-waivered clinicians prescribed any buprenorphine between 2017 and 2021. While the number of waivered clinicians increased significantly during the five-year window, only one out of three prescribed any buprenorphine as of May 2021. Furthermore, the majority of prescriptions were written by clinicians who specialize in treating opioid use disorder. The new study was published as a research letter in JAMA.
New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis & Rheumatology, analysed genetic data on nearly 34,000 people.
Renowned pharmacoepidemiologist, Dr. Tobias Gerhard, is named new director of the Rutgers Institute for Health, Health Care Policy and Aging Research.
For millions of Americans that suffer from seasonal allergies (pollen and mold), climate change is exacerbating an earlier, longer, and overall worse allergy season.
Psilocybin is a hallucinogenic compound found in about 200 mushroom species, including the liberty cap (Psilocybe semilanceata).
Researchers have used Argonne’s Advanced Photon Source to characterize a set of broadly neutralizing antibodies effective against a wide range of coronaviruses.
At the end of 2022, the federal government eliminated the “X waiver,” a major hurdle to providing addiction treatment, but progress needs to be continued, according to the authors of a new Perspective piece published in the New England Journal of Medicine.
A new study conducted by researchers from Regenstrief Institute and the universities of South Carolina and Indiana has found that the most commonly prescribed blood pressure medications, taken for at least six months prior to an intensive care unit (ICU) admission, did not protect against developing delirium in the ICU, regardless of patient age, gender, race, co-morbidities or insurance status.
Safer cancer drugs are now one step closer after a new study led by UCL (University College London) researchers found the likely reason that some treatments damage the heart.
Research supports the promise of psychedelics in treating conditions like depression and post-traumatic stress disorder, but the future regulatory landscape for these drugs remains unclear. Experts from Baylor College of Medicine, the University of Pennsylvania, American University and Harvard Law School call for creativity and collaboration at the federal and state levels in developing policies for the use and oversight of psychedelics and a commitment to developing a strong evidence base for efficacy and safety.
A team of researchers from the University of California, Irvine, have revealed the first crystal structures of the receptor-binding domain of botulinum neurotoxin E (BoNT/E) in complex with its human neuronal receptors, synaptic vesicle glycoprotein 2A (SV2A). This structure and other findings in the new study could be harnessed to engineer new BoNT/E variants with modified specificities toward different SV2 isoforms for new clinical developments.
Researchers at Johns Hopkins University School of Medicine say they have evidence from a new study in rats that spinal cord stimulation (SCS) may be useful in reducing chronic pain in people undergoing active treatment with a common anti-cancer drug.
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a top 50 global specialty pharmaceutical company, today assumes primary commercial leadership for CRYSVITA® (burosumab-twza) injection in the United States and Canada from Ultragenyx Pharmaceutical, Inc., a transition planned for from the start of their decade-long collaboration.
For breast cancer patients undergoing breast reconstruction after mastectomy, avoiding postoperative oral antibiotics does not reduce the risk of infections, reports a study in the May issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer.
MD Anderson and Generate:Biomedicines announced a co-development and commercialization agreement to accelerate novel protein therapies using generative AI.
The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.
As a result of demographic change, the proportion of older oncology patients is rising sharply. Compared to younger patients, cancer treatment is highly individualised due to more frequent and sometimes severe comorbidities, increasing age-related infirmities and reduced physical fitness.
Most medical AI models in use today are trained to perform one or two specific tasks and have limited utility.
Safer and more effective blood thinners could be on the way following a groundbreaking discovery by researchers at UBC and the University of Michigan, published today in Nature Communications.
20240326113011.png&width=400&height=400){kind=logo}
Researchers reporting in ACS Central Science have now developed a system that directly targets and degrades the SARS-CoV-2 viral RNA genome, reducing infection in mice. The method could be adapted to fight off many viruses, as well as treat various diseases.
Treating opioid addiction should be much easier now than it was a few years ago, thanks to pandemic-era rule changes that aim to improve access to buprenorphine, a medicine proven to help in recovery. But a new study shows prescriptions and adherence rates have remained flat.
A study led by the Michigan Psychedelic Center at the University of Michigan Medical School takes a closer look at the neurobiology of psychedelic experiences caused by nitrous oxide, ketamine and LSD.
UCLA Health investigators are leading a new, six-city trial of injectable buprenorphine for treatment of methamphetamine use disorder in adults who also use opioids.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
